More importantly, we found that extending the interventional therapeutic window whereby the first dose of IRAP inhibitor was received at 6 h post-stroke, neuroprotection was still clearly evident by way of improvements in histological and behavioural assessments. This evidence concerns the gene LNPEP and stroke disorder.